China’s SMIC expects flat revenue as drop in low-end orders offsets AI chip growth



Semiconductor Manufacturing International Corp (SMIC), China’s largest contract chipmaker, said it expected first quarter revenue to remain flat as a decline in low-end orders partly offset surging demand for chips used in artificial intelligence applications.

SMIC reported on Tuesday that 2025 revenue increased 16.2 per cent from a year earlier to US$9.3 billion, while net profit surged 39 per cent to US$685.1 million. The growth was mainly due to increases in wafer shipment and utilisation rate, as well as changes in product mix, SMIC said.

However, profit for both the full year and the fourth quarter fell short of analyst estimates, and the company’s Hong Kong-listed shares dropped 3 per cent to HK$69.40 on Wednesday morning. Its Shanghai-listed stock fell 1.3 per cent to 114.70 yuan.

In an earnings call on Wednesday, Zhao Haijun, co-CEO of SMIC, said the company had seen orders from smartphone vendors and makers of other lower-end products “squeezed” by strong demand for AI chips, leading to the company’s flat revenue expectation.

However, he added that the company was “still well positioned in the current industry development cycle”, adding that SMIC would proactively address urgent market demand to drive revenue growth in 2026.

The industry is in the grip of a massive supply crunch for memory chips, as a frantic ramp-up of production for advanced chips to feed demand from AI data centres eats up global wafer capacity and drives up costs across the supply chain. This has forced some companies, including smartphone makers, to reduce production plans.

Shanghai-based SMIC, which anchors Beijing’s drive for semiconductor self-reliance, shipped a total of 9.7 million wafers in 2025, up 21 per cent from 8 million a year earlier. Capacity utilisation rose by 8 percentage points year on year to 93.5 per cent.

  • Related Posts

    China lets yuan rise to strongest level in years as de-dollarisation trend grows

    China’s central bank set the yuan’s daily fixing rate at its strongest level since mid-2023 on Wednesday, as the Chinese currency extended gains with investors increasingly rotating out of US…

    Continue reading
    Fosun Health to build first overseas hospitals in Indonesia amid Chinese ‘go global’ push

    Fosun Health Group, a subsidiary of Fosun Pharmaceutical, said it plans to build its first overseas hospitals in Indonesia amid a push by Chinese healthcare companies to expand abroad. The…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *